Occult hepatitis B virus infection in dialysis patients

A multicentre survey

F. Fabrizi, P. G. Messa, G. Lunghi, F. Aucella, S. Bisegna, S. Mangano, M. Villa, F. Barbisoni, E. Rusconi, P. Martin

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: The epidemiology and clinical significance of occult hepatitis B virus infection (serum hepatitis B surface antigen-negative patients with detectable hepatitis B virus viraemia in serum) remains controversial with only limited information about its prevalence in patients on long-term dialysis. Aim: To address the epidemiology of occult HBV infection in a large cohort of dialysis patients. Methods: We screened a large cohort (n = 585) of Italian chronic dialysis patients; from this population, a group of hepatitis B virus surface antigen seronegative patients (n = 213) was tested by Amplicor hepatitis B virus Monitor Test to detect hepatitis B virus viraemia (hepatitis B virus-DNA) in serum. Results: Occult hepatitis B virus infection was absent (zero of 213 = 0%). Persistent hepatitis B virus surface antigen carriage was less frequent than anti-hepatitis B virus core antibody (anti-hepatitis B core antigen) seropositive status in this study group [1.88% (11 of 585) vs. 36% (216 of 585), P = 0.0001]. No dialysis patients seropositive for anti-hepatitis B core antibody in serum (zero of 123 = 0%) had detectable hepatitis B virus-DNA by polymerase chain reaction technology. No significant association between abnormal biochemical liver tests and serum anti-hepatitis B core antibody was noted in our population. Nominal logistic regression analysis demonstrated an independent and significant relationship between anti-HCV antibody and anti-hepatitis B virus core antibody in serum (Wald chi-square 16.06, P = 0.0001). The rate of seropositive patients for anti-hepatitis B virus core antibody was higher among study patients than controls with normal renal function [36.9% (216 of 585) vs. 21.4% (59 of 275), P = 0.0001]; this difference partially persisted after correction for demographic parameters, and viral markers. Conclusion: In conclusion, occult hepatitis B virus was absent in our study group. Anti-hepatitis B core antibody was significantly related to presence of anti-HCV antibody supporting shared modes of transmission. Clinical studies based on molecular biology techniques provided with higher sensitivity are planned.

Original languageEnglish
Pages (from-to)1341-1347
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume21
Issue number11
DOIs
Publication statusPublished - Jun 1 2005

Fingerprint

Virus Diseases
Hepatitis B virus
Hepatitis B Antibodies
Dialysis
Hepatitis B Surface Antigens
Serum
Hepatitis C Antibodies
Viremia
Epidemiology
Surveys and Questionnaires
Hepatitis B Core Antigens
DNA-Directed DNA Polymerase
Population
Molecular Biology
Biomarkers
Logistic Models
Regression Analysis
Demography
Technology
Kidney

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Occult hepatitis B virus infection in dialysis patients : A multicentre survey. / Fabrizi, F.; Messa, P. G.; Lunghi, G.; Aucella, F.; Bisegna, S.; Mangano, S.; Villa, M.; Barbisoni, F.; Rusconi, E.; Martin, P.

In: Alimentary Pharmacology and Therapeutics, Vol. 21, No. 11, 01.06.2005, p. 1341-1347.

Research output: Contribution to journalArticle

Fabrizi, F. ; Messa, P. G. ; Lunghi, G. ; Aucella, F. ; Bisegna, S. ; Mangano, S. ; Villa, M. ; Barbisoni, F. ; Rusconi, E. ; Martin, P. / Occult hepatitis B virus infection in dialysis patients : A multicentre survey. In: Alimentary Pharmacology and Therapeutics. 2005 ; Vol. 21, No. 11. pp. 1341-1347.
@article{f5e37b17b22a463f80433234272dd5de,
title = "Occult hepatitis B virus infection in dialysis patients: A multicentre survey",
abstract = "Background: The epidemiology and clinical significance of occult hepatitis B virus infection (serum hepatitis B surface antigen-negative patients with detectable hepatitis B virus viraemia in serum) remains controversial with only limited information about its prevalence in patients on long-term dialysis. Aim: To address the epidemiology of occult HBV infection in a large cohort of dialysis patients. Methods: We screened a large cohort (n = 585) of Italian chronic dialysis patients; from this population, a group of hepatitis B virus surface antigen seronegative patients (n = 213) was tested by Amplicor hepatitis B virus Monitor Test to detect hepatitis B virus viraemia (hepatitis B virus-DNA) in serum. Results: Occult hepatitis B virus infection was absent (zero of 213 = 0{\%}). Persistent hepatitis B virus surface antigen carriage was less frequent than anti-hepatitis B virus core antibody (anti-hepatitis B core antigen) seropositive status in this study group [1.88{\%} (11 of 585) vs. 36{\%} (216 of 585), P = 0.0001]. No dialysis patients seropositive for anti-hepatitis B core antibody in serum (zero of 123 = 0{\%}) had detectable hepatitis B virus-DNA by polymerase chain reaction technology. No significant association between abnormal biochemical liver tests and serum anti-hepatitis B core antibody was noted in our population. Nominal logistic regression analysis demonstrated an independent and significant relationship between anti-HCV antibody and anti-hepatitis B virus core antibody in serum (Wald chi-square 16.06, P = 0.0001). The rate of seropositive patients for anti-hepatitis B virus core antibody was higher among study patients than controls with normal renal function [36.9{\%} (216 of 585) vs. 21.4{\%} (59 of 275), P = 0.0001]; this difference partially persisted after correction for demographic parameters, and viral markers. Conclusion: In conclusion, occult hepatitis B virus was absent in our study group. Anti-hepatitis B core antibody was significantly related to presence of anti-HCV antibody supporting shared modes of transmission. Clinical studies based on molecular biology techniques provided with higher sensitivity are planned.",
author = "F. Fabrizi and Messa, {P. G.} and G. Lunghi and F. Aucella and S. Bisegna and S. Mangano and M. Villa and F. Barbisoni and E. Rusconi and P. Martin",
year = "2005",
month = "6",
day = "1",
doi = "10.1111/j.1365-2036.2005.02501.x",
language = "English",
volume = "21",
pages = "1341--1347",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "11",

}

TY - JOUR

T1 - Occult hepatitis B virus infection in dialysis patients

T2 - A multicentre survey

AU - Fabrizi, F.

AU - Messa, P. G.

AU - Lunghi, G.

AU - Aucella, F.

AU - Bisegna, S.

AU - Mangano, S.

AU - Villa, M.

AU - Barbisoni, F.

AU - Rusconi, E.

AU - Martin, P.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Background: The epidemiology and clinical significance of occult hepatitis B virus infection (serum hepatitis B surface antigen-negative patients with detectable hepatitis B virus viraemia in serum) remains controversial with only limited information about its prevalence in patients on long-term dialysis. Aim: To address the epidemiology of occult HBV infection in a large cohort of dialysis patients. Methods: We screened a large cohort (n = 585) of Italian chronic dialysis patients; from this population, a group of hepatitis B virus surface antigen seronegative patients (n = 213) was tested by Amplicor hepatitis B virus Monitor Test to detect hepatitis B virus viraemia (hepatitis B virus-DNA) in serum. Results: Occult hepatitis B virus infection was absent (zero of 213 = 0%). Persistent hepatitis B virus surface antigen carriage was less frequent than anti-hepatitis B virus core antibody (anti-hepatitis B core antigen) seropositive status in this study group [1.88% (11 of 585) vs. 36% (216 of 585), P = 0.0001]. No dialysis patients seropositive for anti-hepatitis B core antibody in serum (zero of 123 = 0%) had detectable hepatitis B virus-DNA by polymerase chain reaction technology. No significant association between abnormal biochemical liver tests and serum anti-hepatitis B core antibody was noted in our population. Nominal logistic regression analysis demonstrated an independent and significant relationship between anti-HCV antibody and anti-hepatitis B virus core antibody in serum (Wald chi-square 16.06, P = 0.0001). The rate of seropositive patients for anti-hepatitis B virus core antibody was higher among study patients than controls with normal renal function [36.9% (216 of 585) vs. 21.4% (59 of 275), P = 0.0001]; this difference partially persisted after correction for demographic parameters, and viral markers. Conclusion: In conclusion, occult hepatitis B virus was absent in our study group. Anti-hepatitis B core antibody was significantly related to presence of anti-HCV antibody supporting shared modes of transmission. Clinical studies based on molecular biology techniques provided with higher sensitivity are planned.

AB - Background: The epidemiology and clinical significance of occult hepatitis B virus infection (serum hepatitis B surface antigen-negative patients with detectable hepatitis B virus viraemia in serum) remains controversial with only limited information about its prevalence in patients on long-term dialysis. Aim: To address the epidemiology of occult HBV infection in a large cohort of dialysis patients. Methods: We screened a large cohort (n = 585) of Italian chronic dialysis patients; from this population, a group of hepatitis B virus surface antigen seronegative patients (n = 213) was tested by Amplicor hepatitis B virus Monitor Test to detect hepatitis B virus viraemia (hepatitis B virus-DNA) in serum. Results: Occult hepatitis B virus infection was absent (zero of 213 = 0%). Persistent hepatitis B virus surface antigen carriage was less frequent than anti-hepatitis B virus core antibody (anti-hepatitis B core antigen) seropositive status in this study group [1.88% (11 of 585) vs. 36% (216 of 585), P = 0.0001]. No dialysis patients seropositive for anti-hepatitis B core antibody in serum (zero of 123 = 0%) had detectable hepatitis B virus-DNA by polymerase chain reaction technology. No significant association between abnormal biochemical liver tests and serum anti-hepatitis B core antibody was noted in our population. Nominal logistic regression analysis demonstrated an independent and significant relationship between anti-HCV antibody and anti-hepatitis B virus core antibody in serum (Wald chi-square 16.06, P = 0.0001). The rate of seropositive patients for anti-hepatitis B virus core antibody was higher among study patients than controls with normal renal function [36.9% (216 of 585) vs. 21.4% (59 of 275), P = 0.0001]; this difference partially persisted after correction for demographic parameters, and viral markers. Conclusion: In conclusion, occult hepatitis B virus was absent in our study group. Anti-hepatitis B core antibody was significantly related to presence of anti-HCV antibody supporting shared modes of transmission. Clinical studies based on molecular biology techniques provided with higher sensitivity are planned.

UR - http://www.scopus.com/inward/record.url?scp=20444451564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444451564&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02501.x

DO - 10.1111/j.1365-2036.2005.02501.x

M3 - Article

VL - 21

SP - 1341

EP - 1347

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 11

ER -